Unipharma Ampoules And Vials Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 03-07-2024
- Paid Up Capital ₹ 2.50 Cr
as on 03-07-2024
- Company Age 22 Year,
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.88 Cr
as on 03-07-2024
- Revenue 40.31%
(FY 2022)
- Profit 110.97%
(FY 2022)
- Ebitda 1521.95%
(FY 2022)
- Net Worth 0.25%
(FY 2022)
- Total Assets 16.27%
(FY 2022)
About Unipharma Ampoules And Vials
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.50 Cr.
The company currently has active open charges totaling ₹1.88 Cr.
Naser Shaikh, Parveen Tamboli, and Chandravilas Durve serve as directors at the Company.
- CIN/LLPIN
U26103PN2002PTC017532
- Company No.
017532
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Dec 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Unipharma Ampoules And Vials?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naser Shaikh  | Additional Director | 08-May-2023 | Current |
| Parveen Tamboli | Director | 15-May-2023 | Current |
| Chandravilas Durve | Additional Director | 01-Dec-2021 | Current |
Financial Performance of Unipharma Ampoules And Vials.
Unipharma Ampoules And Vials Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 40.31% increase. The company also saw a substantial improvement in profitability, with a 110.97% increase in profit. The company's net worth moved up by a moderate rise of 0.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unipharma Ampoules And Vials?
In 2022, Unipharma Ampoules And Vials had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dena Bank Creation Date: 28 Aug 2003 | ₹1.50 Cr | Open |
Dena Bank Creation Date: 22 Aug 2003 | ₹3.75 M | Open |
How Many Employees Work at Unipharma Ampoules And Vials?
Unipharma Ampoules And Vials has a workforce of 20 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unipharma Ampoules And Vials, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unipharma Ampoules And Vials's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_303470.webp){kind=small}
